Mass spectrometry based proteomic profiling for pancreatic cancer.

N. Pawa,J. M. Wright,T. Arulampalam

DOI: https://doi.org/10.6092/1590-8577/3427

2010-09-06

Abstract:No abstract available. Image: Mass spectrometer schematic ( Wikimedia Commons , by Devon Fyson)

What problem does this paper attempt to address?

Essential role of a kinesin-like protein in Arabidopsis trichome morphogenesis.

David G. Oppenheimer,Mary A. Pollock,Joshua Vacik,Daniel B. Szymanski,Brad L. Ericson,Kenneth A. Feldmann,M. Marks

DOI: https://doi.org/10.1073/PNAS.94.12.6261

1997-06-10

Abstract:Little is known about how cell shape is controlled. We are using the morphogenesis of trichomes (plant hairs) on the plant Arabidopsis thaliana as a model to study how cell shape is controlled. Wild-type Arabidopsis trichomes are large, single epidermal cells with a stalk and three or four branches, whereas in zwichel (zwi) mutants the trichomes have a shortened stalk and only two branches. To further understand the role of the ZWI gene in trichome morphogenesis we have cloned the wild-type ZWICHEL (ZWI) gene by T-DNA tagging, and report here that it encodes a member of the kinesin superfamily of microtubule motor proteins. Kinesin proteins transport diverse cellular materials in a directional manner along microtubules. Kinesin-like proteins are characterized by a highly conserved "head" region that comprises the motor domain, and a nonconserved "tail" region that is thought to participate in recognition and binding of the appropriate cargo.
Predicting rib fracture risk with whole-body finite element models: development and preliminary evaluation of a probabilistic analytical framework.

J. Forman,R. Kent,K. Mroz,B. Pipkorn,O. Bostrom,M. Seguí-Gómez

Abstract:This study sought to develop a strain-based probabilistic method to predict rib fracture risk with whole-body finite element (FE) models, and to describe a method to combine the results with collision exposure information to predict injury risk and potential intervention effectiveness in the field. An age-adjusted ultimate strain distribution was used to estimate local rib fracture probabilities within an FE model. These local probabilities were combined to predict injury risk and severity within the whole ribcage. The ultimate strain distribution was developed from a literature dataset of 133 tests. Frontal collision simulations were performed with the THUMS (Total HUman Model for Safety) model with four levels of delta-V and two restraints: a standard 3-point belt and a progressive 3.5-7 kN force-limited, pretensioned (FL+PT) belt. The results of three simulations (29 km/h standard, 48 km/h standard, and 48 km/h FL+PT) were compared to matched cadaver sled tests. The numbers of fractures predicted for the comparison cases were consistent with those observed experimentally. Combining these results with field exposure informantion (ΔV, NASS-CDS 1992-2002) suggests a 8.9% probability of incurring AIS3+ rib fractures for a 60 year-old restrained by a standard belt in a tow-away frontal collision with this restraint, vehicle, and occupant configuration, compared to 4.6% for the FL+PT belt. This is the first study to describe a probabilistic framework to predict rib fracture risk based on strains observed in human-body FE models. Using this analytical framework, future efforts may incorporate additional subject or collision factors for multi-variable probabilistic injury prediction.
Effect of Selenium on the Expression of Fas/FasL in T Lymphocyte Anti Colonic Cancer Cells

Min Zheng

2001-01-01

Abstract:Objective To observe the effects of selenium on the expression of Fas/FasL in T lymphocyte anti colonic cancer cells. Methods Selenocysteine served as an influencing factor, T lymphocyte as an effector and human colonic tumor cell (LoVo cell: human colonic adenocarcinoma) as a target. MTT and acridine orange dying were used to measure LoVo cells apoptosis, and RT PCR and hybridization techniques used to identify the levels of Fas/FasL and TNF expressed by T cells or target cells after use of selenium or not. Results MTT and acridine orange dying showed that selenium enhanced T lymphocyte anti tumor function [(25.12±3.91)%,(46.17±3.68)% respectively,( P 0.05)],and induced LoVo cells apoptosis and this effect was [ (18.6±4.1)%, (32.7±2.1)% respectively,( P 0.05)] at the proper concentration (0.5～1.0 mg/L) in time and dose dependent manners. And the levels of FasL and Fas mRNA expressed by target cells (LoVo cell) and effectors were increased. Conclusion Selenium enhanced T lymphocyte anti tumor function, which was related to high levels of Fas/FasL expression. [
Response Surface Methodology Optimizes Selenium Inhibition of Prostate Cancer PC-3 Cell Viability

Andrew Whitcomb,Xiuqi Li,John Lawson,Merrill Christensen,Xiqui Li

DOI: https://doi.org/10.1016/j.jtemb.2024.127414

IF: 3.995

2024-02-01

Journal of Trace Elements in Medicine and Biology

Abstract:BACKGROUND: The rising incidence of prostate cancer in the U.S. necessitates innovative therapeutic approaches to this disease. Though extensive research has studied Selenium as an anticarcinogen against prostate cancer, results have varied due to overlooked experimental confounds. Recent studies have identified differential effects of various selenium compounds on prostate cancer cells. This study leverages Mixture Design Response Surface Methodology to characterize the ideal combination of select Se forms against the PC-3 prostate cancer cell line.METHODS: The PC-3 cell line was chosen as a model for its representation of advanced-stage malignancy. Three Se compounds-sodium selenite, methylseleninic acid, and nano-selenium-were selected for their promising antineoplastic potential. Nano-Se particles were synthesized and subsequently characterized by transmission electron microscopy. Cells were cultured, treated with Se compounds, and assessed for viability using an Alamar Blue Assay. IC<sub>50</sub> values of individual Se compounds were determined, and treatment combinations evaluated. In collaboration with statical modeling experts, MDRSM was utilized to optimize Se compound combinations.RESULTS: Absolute IC<sub>50</sub> values were identified for methylseleninic acid (5.01 μmol/L), sodium selenite (13.8 μmol/L), and nano-selenium (14.6 μmol/L). Combining methylseleninic acid and sodium selenite resulted in only 5% PC-3 cell viability, whereas individual treatments reduced viability by approximately 45%. Among the tested mixtures, the 50:50 combination of MSA and sodium selenite most effectively decreased PC-3 cell viability. Regression analysis indicated the special cubic model had a strong fit (multiple r² = 0.9853), predicting maximum cell viability reduction from the methylseleninic acid and selenite mixture.CONCLUSION: The specific form of Selenium plays a pivotal role in determining its physiological effects and therapeutic potential against prostate cancer. All three selenium compounds showed variable antineoplastic effects, with a 50:50 mixture of methylseleninic acid and selenite exhibiting optimal results. Nano-selenium, when combined with selenite, showed no additive effect, implying a shared mechanism of action. Our research underscores the critical need to consider Se compound forms as distinct entities in prostate cancer treatment and encourages further exploration of Se compounds against prostate cancer.

biochemistry & molecular biology,endocrinology & metabolism
Effect of selenium-containing compounds on hepatic chemoprotective enzymes in mice

Wael M El-Sayed,Tarek Aboul-Fadl,John G Lamb,Jeanette C Roberts,Michael R Franklin

DOI: https://doi.org/10.1016/j.tox.2005.12.016

IF: 4.571

2006-03-15

Toxicology

Abstract:Selenite and organoselenium compounds have been examined at supranutritional levels for their ability to influence the activity and mRNA levels of chemoprotective enzymes in the livers of selenium-sufficient mice and the changes compared to those elicited by oltipraz. Compounds investigated included novel selenocysteine prodrugs that have previously been evaluated for their ability to reduce the tumorigenicity of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in mice. Following seven daily doses (i.g.), all compounds except 2-methylselenazolidine-4(R)-carboxylic acid (MSCA) increased thioredoxin reductase activity (43-92%) but only for 2-oxoselenazolidine-4(R)-carboxylic acid (OSCA) was there an accompanying increase in mRNA. No compound enhanced glutathione peroxidase activity, although sodium selenite significantly elevated the mRNA of this enzyme. Oltipraz was an efficacious inducer of both thioredoxin reductase and glutathione peroxidase mRNAs. Sodium selenite, selenazolidine-4(R)-carboxylic acid (SCA), and OSCA elevated NAD(P)H-quinone oxidoreductase mRNA but only for OSCA was the elevation in mRNA accompanied by an increase in enzyme activity. L-Selenocystine significantly increased this activity without increasing mRNA levels. Sodium selenite, L-selenocystine, L-selenomethionine, and Se-methyl-L-selenocysteine all enhanced glutathione S-transferase activity. The increased activity with sodium selenite was accompanied by increases in mRNAs of Gst alpha, Gst mu and Gst pi classes, while for L-selenocystine and Se-methyl-L-selenocysteine, only an elevation in the mRNA for the Gst alpha class was observed. Gst alpha and Gst mu class mRNAs were elevated by OSCA without a significant elevation in enzyme activity. SCA and MSCA both elevated a Gst pi mRNA and MSCA elevated Gst mu in addition. By comparison, oltipraz only significantly elevated the mRNA of Gst mu, adding to the conclusion that across the entire study, no selenium compound appears to be acting purely through the antioxidant response typified by oltipraz. Despite their chemical similarity, the three cysteine prodrugs, SCA, MSCA, and OSCA, each produced its own unique pattern of effects on protective enzymes and none was identical to the pattern elicited by sodium selenite, L-selenocystine, L-selenomethionine, and Se-methyl-L-selenocysteine. The study also shows that after 7 days of administration, there was only occasional concordance between elevations in mRNA and enzyme activity for any selenium compound and for any protective enzyme, there was no response in common for all selenium compounds.
Preliminary Study of Selenium (Se) Toxicity in Human Prostate Carcinoma (PC3) Cells with the Overexpression of Selenocysteine Synthase ( SecS ) Gene

Tomilowo Abijo,Jia Xie

DOI: https://doi.org/10.4236/OJGEN.2016.64009

2016-10-27

Abstract:Selenium (Se) is a trace element required for normal body function. Its supplementation of human diet at standard optimum amount prevents oxidative damages in cells and could be a viable method in the prevention of diseases related to DNA damage, including cancer, neurodegenerative diseases and aging. While Se anticancer properties have been linked to its ability to remove excess Reactive Oxygen Species (ROS) in cells, the underlying molecular mechanism remains unknown. Recent studies have shown that the removal of ROS alone cannot account for Se anticancer properties. To really comprehend the molecular basis of Se anticancer properties, current researches now focus on the metabolism of Se in the cell, especially Se-containing amino acids. Selenocysteine (Sec) is a novel amino acid and one of the selenium-containing compounds in the cell. It is essential in the maintenance of the integrity of its parent proteins, some of which include enzymes such as Glutathione Peroxidases (GPXs) and Thioredoxin Reductases (TrXs). We propose in this study that the overproduction of Sec via the overexpression of Selenocysteine synthase (SecS) gene and Se supplementation induced cell death in Prostate Carcinoma (PC-3) cells. Although the mechanism underlying the cell death induction is unknown, we propose it could be due to the random incorporation of Sec into proteins at high concentration, causing premature protein degradation and cell death. The outcome of this study showed that increasing the concentration of intracellular Se-containing amino acids may provide important clinical implications for the treatment of cancer.

Biology,Medicine
Hyaluronan participates in the epidermal response to disruption of the permeability barrier in vivo.

E. Maytin,Helen H. Chung,V. Mani Seetharaman

DOI: https://doi.org/10.1016/S0002-9440(10)63391-3

IF: 5.77

2004-10-01

American Journal Of Pathology

Abstract:
Selenomethionine Stimulates MAPK (ERK) Phosphorylation, Protein Oxidation, and DNA Synthesis in Gastric Cancer Cells

Archana Verma,Mary Jo Atten,Bashar M. Attar,Oksana Holian

DOI: https://doi.org/10.1207/s15327914nc4902_10

2004-07-01

Nutrition and Cancer

Abstract:Selenium is an essential trace element and is required for the synthesis of cellular enzymes that protect against oxidative stress. Epidemiological findings indicate that low selenium intake is associated with increased cancer risk, and, although the majority of studies show that exposure of transformed cells to selenium results in apoptotic cell death, there are reports indicating that cells exposure to low selenium concentrations promotes cellular proliferation. Gastric adenocarcinoma SNU-1 cells responded to selenomethionine with a biphasic proliferative curve: enhanced incorporation of 3H-thymidine into DNA within a very narrow range of selenomethionine concentrations followed by decreased 3H-thymidine uptake at higher levels. Concentrations of selenomethionine that stimulate cellular proliferation also induce cellular oxidation and phosphorylation of MAPK (ERK), a component of cell signaling cascades. MAPK (ERK) phosphorylation is synonymous with MAPK activation and enhanced cell growth. Our findings support previous observations of enhanced proliferation in response to low levels of selenium and suggest that, at certain concentrations, selenomethionine induces mild oxidative stress that, in turn, stimulates DNA synthesis.
Selenium and the 15kDa Selenoprotein Impact Colorectal Tumorigenesis by Modulating Intestinal Barrier Integrity

Jessica A Canter,Sarah E Ernst,Kristin M Peters,Bradley A Carlson,Noelle R J Thielman,Lara Grysczyk,Precious Udofe,Yunkai Yu,Liang Cao,Cindy D Davis,Vadim N Gladyshev,Dolph L Hatfield,Petra A Tsuji

DOI: https://doi.org/10.3390/ijms221910651

2021-09-30

Abstract:Selenoproteins play important roles in many cellular functions and biochemical pathways in mammals. Our previous study showed that the deficiency of the 15 kDa selenoprotein (Selenof) significantly reduced the formation of aberrant crypt foci (ACF) in a mouse model of azoxymethane (AOM)-induced colon carcinogenesis. The objective of this study was to examine the effects of Selenof on inflammatory tumorigenesis, and whether dietary selenium modified these effects. For 20 weeks post-weaning, Selenof-knockout (KO) mice and littermate controls were fed diets that were either deficient, adequate or high in sodium selenite. Colon tumors were induced with AOM and dextran sulfate sodium. Surprisingly, KO mice had drastically fewer ACF but developed a similar number of tumors as their littermate controls. Expression of genes important in inflammatory colorectal cancer and those relevant to epithelial barrier function was assessed, in addition to structural differences via tissue histology. Our findings point to Selenof's potential role in intestinal barrier integrity and structural changes in glandular and mucin-producing goblet cells in the mucosa and submucosa, which may determine the type of tumor developing.
Survivin gene silencing sensitizes prostate cancer cells to selenium growth inhibition

Xichun Liu,Ruijuan Gao,Yan Dong,Lifang Gao,Yanying Zhao,Lijuan Zhao,Xuejian Zhao,Haitao Zhang

DOI: https://doi.org/10.1186/1471-2407-10-418

IF: 4.638

2010-08-10

BMC Cancer

Abstract:Background: Prostate cancer is a leading cause of cancer-related death in men worldwide. Survivin is a member of the inhibitor of apoptosis (IAP) protein family that is expressed in the majority of human tumors including prostate cancer, but is barely detectable in terminally differentiated normal cells. Downregulation of survivin could sensitize prostate cancer cells to chemotherapeutic agents in vitro and in vivo. Selenium is an essential trace element. Several studies have shown that selenium compounds inhibit the growth of prostate cancer cells. The objective of this study is to investigate whether survivin gene silencing in conjunction with selenium treatment could enhance the therapeutic efficacy for prostate cancer and to elucidate the underlying mechanisms. Methods: Expression of survivin was analyzed in a collection of normal and malignant prostatic tissues by immunohistochemical staining. In vitro studies were conducted in PC-3M, C4-2B, and 22Rv1 prostate cancer cells. The effect of selenium on survivin expression was analyzed by Western blotting and semi-quantitative RT-PCR. Survivin gene knockdown was carried out by transfecting cells with a short hairpin RNA (shRNA) designed against survivin. Cell proliferation was quantitated by the 3-(4,5-Dimethylthiazol-2-yl)- 2,5-Diphenyltetrazolium Bromide (MTT) assay and apoptosis by propidium iodide staining followed by flow cytometry analysis. Finally, in vivo tumor growth assay was performed by establishing PC-3M xenograft in nude mice and monitoring tumor growth following transfection and treatment. Results: We found that survivin was undetectable in normal prostatic tissues but was highly expressed in prostate cancers. Survivin knockdown or selenium treatment inhibited the growth of prostate cancer cells, but the selenium effect was modest. In contrast to what have been observed in other cell lines, selenium treatment had little or no effect on survivin expression in several androgen-independent prostate cancer cell lines. Survivin knockdown sensitized these cells to selenium growth inhibition and apoptosis induction. In nude mice bearing PC-3M xenografts, survivin knockdown synergizes with selenium in inhibiting tumor growth. Conclusions: Selenium could inhibit the growth of hormone-refractory prostate cancer cells both in vitro and in vivo, but the effects were modest. The growth inhibition was not mediated by downregulating survivin expression. Survivin silencing greatly enhanced the growth inhibitory effects of selenium.
Differential epigenetic profiles induced by sodium selenite in breast cancer cells

Zhuo-Zhi Liang,Rui-Mei Zhu,Yue-Lin Li,Hong-Mei Jiang,Ruo-Bi Li,Qing Wang,Lu-Ying Tang,Ze-Fang Ren

DOI: https://doi.org/10.1016/j.jtemb.2020.126677

IF: 3.995

2021-03-01

Journal of Trace Elements in Medicine and Biology

Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Objectives</h3><p>Selenium (Se) was a potential anticancer micronutrient with proposed epigenetic effect. However, the Se-induced epigenome in breast cancer cells was yet to be studied.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>The profiles of DNA methylation, microRNA (miRNA), long non-coding RNA (lncRNA), and message RNA (mRNA) in breast cancer cells treated with sodium selenite were examined by microarrays. We verified the epigenetic modifications by integrating their predicted target genes and differentially expressed mRNAs. The epigenetically regulated genes were further validated in a breast cancer cohort by associating with tumor progression. We conducted a series of bioinformatics analyses to assess the biological function of these validated genes and identified the critical genes.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>The Se-induced epigenome regulated the expression of 959 genes, and 349 of them were further validated in the breast cancer cohort. Biological function analyses suggested that these validated genes were enriched in several cancer-related pathways, such as PI3K/Akt and metabolic pathways. Based on the degrees of expression change, hazard ratio difference, and connectivity, <em>NEDD4L</em> and <em>FMO5</em> were identified as the critical genes.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>These results confirmed the epigenetic effects of sodium selenite and revealed the epigenetic profiles in breast cancer cells, which would help understand the mechanisms of Se against breast cancer.</p>

biochemistry & molecular biology,endocrinology & metabolism
Studying the impact of selenium complex chemical structure on collagen-starch hydrogels for enhanced tissue growth

Maria P. Flores-Urquieta,Jesús A. Claudio-Rizo,Denis A. Cabrera-Munguía,Lucía F. Cano-Salazar,Tirso E. Flores-Guía,Roberto Espinoza-Neira,Juan J. Becerra-Rodriguez

DOI: https://doi.org/10.1080/1539445x.2024.2434875

2024-11-29

Soft Materials

Abstract:Selenium complexes modifying their chemical structure through the variation of amino acids such as L-phenylalanine, L-histidine, and L-tryptophan were dispersed in collagen-starch hydrogels (1 wt.%), generating the (Se-F), (Se-H), and (Se-T) biomatrices, respectively. SEM/EDS analysis confirmed a uniform selenium distribution, with (Se-H) biomatrix displaying the largest aggregates, influencing the formation and size of aggregates within the biopolymer matrix. All matrices exhibited a semicrystalline nature; notably (Se-T) decreased fibrillar structure crystallinity of collagen. Physicochemical assessments revealed (Se-H) with the shortest gelation time (10 ± 1 minutes), highest swelling (4500 ± 230%) and superior resistance to proteolytic degradation. (Se-T) demonstrated the highest crosslinking index (52 ± 4%), while (Se-F) was characterized by having the highest storage modulus (840 Pa at 1 hz), enabling the sustained release of methylene blue for up to 7 days. Upon contact with commercial plant substrate, all matrices showed negligible mass variation. Biological findings showcased (Se-F) stimulating monocyte metabolism and proliferation, while (Se-H) fostered fibroblast metabolism, proliferation, and interleukin-10 (IL-10) secretion in monocytes, alongside reduced tumor necrosis factor-alpha (TNF-α) secretion. All matrices decreased TNF-α secretion in monocytes, signifying potential as advanced wound healing dressings. For plant tissue, all matrices enhanced tomato cell metabolism and proliferation. Seeds grown on commercial plant substrate revealed (Se-F) yielding plants with larger stem sizes, while (Se-T) resulted in higher leaf counts within 30 days, indicating their potential agricultural applications.

materials science, multidisciplinary
Mitochondria-Mediated Protein Regulation Mechanism of Polymorphs-Dependent Inhibition of Nanoselenium on Cancer Cells

Ge Wang,Yuming Guo,Gai Yang,Lin Yang,Xiaoming Ma,Kui Wang,Lin Zhu,Jiaojiao Sun,Xiaobing Wang,Hua Zhang

DOI: https://doi.org/10.1038/srep31427

IF: 4.6

2016-08-01

Scientific Reports

Abstract:The present study was (i) to prepare two types of selenium nanoparticles, namely an amorphous form of selenium quantum dots (A-SeQDs) and a crystalline form of selenium quantum dots (C-SeQDs); and (ii) to investigate the nano-bio interactions of A-SeQDs and C-SeQDs in MCF-7, HepG2, HeLa, NIH/3T3, L929 cells and BRL-3A cells. It was found that A-SeQDs could induce the mitochondria-mediated apoptosis, necrosis and death of cells, while C-SeQDs had much weaker effects. This polymorphs-dependent anti-proliferative activity of nano-selenium was scarcely reported. Further investigation demonstrated that A-SeQDs could differentially regulate 61 proteins and several pathways related to stress response, protein synthesis, cell migration and cell cycle, including “p38 MAPK Signaling”, “p53 Signaling”, “14-3-3-mediated Signaling”, “p70S6K Signaling” and “Protein Ubiquitination Pathway”. This was the first report to demonstrate the involvement of protein synthesis and post-translational modification pathways in the anti-proliferative activity associated with NMs. Compared with previously fragmentary studies, this study use a nanomics approach combining bioinformatics and proteomics to systematically investigate the nano-bio interactions of selenium nanoparticles in cancer cells.

multidisciplinary sciences
Selenium speciation studies in cancer patients to evaluate the responses of biomarkers of selenium status to different selenium compounds

M. Estela del Castillo Busto,Christian Ward-Deitrich,Stephen O. Evans,Margaret P. Rayman,Michael B. Jameson,Heidi Goenaga-Infante

DOI: https://doi.org/10.1007/s00216-024-05141-y

2024-01-30

Analytical and Bioanalytical Chemistry

Abstract:Abstract This work presents the first systematic comparison of selenium (Se) speciation in plasma from cancer patients treated orally with three Se compounds (sodium selenite, SS; L-selenomethionine, SeMet; or Se-methylselenocysteine, MSC) at 400 μg/day for 28 days. The primary goal was to investigate how these chemical forms of Se affect the plasma Se distribution, aiming to identify the most effective Se compound for optimal selenoprotein expression. This was achieved using methodology based on HPLC-ICP-MS after sample preparation/fractionation approaches. Measurements of total Se in plasma samples collected before and after 4 weeks of treatment showed that median total Se levels increased significantly from 89.6 to 126.4 μg kg −1 Se ( p < 0.001), particularly when SeMet was administered (190.4 μg kg −1 Se). Speciation studies showed that the most critical differences between treated and baseline samples were seen for selenoprotein P (SELENOP) and selenoalbumin after administration with MSC ( p = 5.8 × 10 −4 ) and SeMet ( p = 6.8 × 10 −5 ), respectively. Notably, selenosugar-1 was detected in all low-molecular-weight plasma fractions following treatment, particularly with MSC. Two different chromatographic approaches and spiking experiments demonstrated that about 45% of that increase in SELENOP levels (to ~ 8.8 mg L −1 ) with SeMet is likely due to the non-specific incorporation of SeMet into the SELENOP affinity fraction. To the authors’ knowledge, this has not been reported to date. Therefore, SELENOP is probably part of both the regulated (55%) and non-regulated (45%) Se pools after SeMet administration, whereas SS and MSC mainly contribute to the regulated one. Graphical abstract

chemistry, analytical,biochemical research methods
The Nutritional Prevention of Cancer: 400 Mcg Per Day Selenium Treatment

Mary E. Reid,Anna J. Duffield-Lillico,Elizabeth Slate,Nachimuthu Natarajan,Bruce Turnbull,Elizabeth Jacobs,Gerald F. Combs,David S. Alberts,Larry C. Clark †,James R. Marshall,Mary Reid,Anna Duffield-Lillico,Gerald Combs,David Alberts,Larry Clark,James Marshall

DOI: https://doi.org/10.1080/01635580701684856

2008-03-01

Nutrition and Cancer

Abstract:Nonexperimental studies suggest that individuals with higher selenium (Se) status are at decreased risk of cancer. The Nutritional Prevention of Cancer (NPC) study randomized 1,312 high-risk dermatology patients to 200-mcg/day of Se in selenized yeast or a matched placebo; selenium supplementation decreased the risk of lung, colon, prostate, and total cancers but increased the risk of nonmelanoma skin cancer. In this article, we report on a small substudy in Macon, GA, which began in 1989 and randomized 424 patients to 400-mcg/day of Se or to matched placebo. The subjects from both arms had similar baseline Se levels to those treated by 200 mcg, and those treated with 400-mcg attained plasma Se levels much higher than subjects treated with 200 mcg. The 200-mcg/day Se treatment decreased total cancer incidence by a statistically significant 25%; however, 400-mcg/day of Se had no effect on total cancer incidence.
Antitumor Effects of Selenium

Seung Jo Kim,Min Chul Choi,Jong Min Park,An Sik Chung

DOI: https://doi.org/10.3390/ijms222111844

IF: 5.6

2021-10-31

International Journal of Molecular Sciences

Abstract:Functions of selenium are diverse as antioxidant, anti-inflammation, increased immunity, reduced cancer incidence, blocking tumor invasion and metastasis, and further clinical application as treatment with radiation and chemotherapy. These functions of selenium are mostly related to oxidation and reduction mechanisms of selenium metabolites. Hydrogen selenide from selenite, and methylselenol (MSeH) from Se-methylselenocyteine (MSeC) and methylseleninicacid (MSeA) are the most reactive metabolites produced reactive oxygen species (ROS); furthermore, these metabolites may involve in oxidizing sulfhydryl groups, including glutathione. Selenite also reacted with glutathione and produces hydrogen selenide via selenodiglutathione (SeDG), which induces cytotoxicity as cell apoptosis, ROS production, DNA damage, and adenosine-methionine methylation in the cellular nucleus. However, a more pronounced effect was shown in the subsequent treatment of sodium selenite with chemotherapy and radiation therapy. High doses of sodium selenite were effective to increase radiation therapy and chemotherapy, and further to reduce radiation side effects and drug resistance. In our study, advanced cancer patients can tolerate until 5000 μg of sodium selenite in combination with radiation and chemotherapy since the half-life of sodium selenite may be relatively short, and, further, selenium may accumulates more in cancer cells than that of normal cells, which may be toxic to the cancer cells. Further clinical studies of high amount sodium selenite are required to treat advanced cancer patients.

biochemistry & molecular biology,chemistry, multidisciplinary
Deregulated glutamate to pro-collagen conversion is associated with adverse outcome in lung cancer and may be targeted by renin-angiotensin-aldosterone system (RAS) inhibition

Florian Kocher,Piotr Tymoszuk,Arno Amann,Susanne Sprung,Stefan Salcher,Sophia Daum,Johannes Haybaeck,Gabriel Rinnerthaler,Florian Huemer,Diego Kauffmann-Guerrero,Amanda Tufman,Andreas Seeber,Dominik Wolf,Andreas Pircher

DOI: https://doi.org/10.1016/j.lungcan.2021.06.020

IF: 6.081

Lung Cancer

Abstract:Background: The tumor-microenvironment (TME) represents an attractive therapeutic target in NSCLC and plays an important role for efficacy of cancer therapeutics. We hypothesized that upregulation of collagen synthesis might be associated with adverse outcome in NSCLC. Literature evidence suggests that renin-angiotensin system inhibitors (RASi) decrease collagen deposition. Therefore, we aimed to explore the prognostic role of RASi intake and their influence on the TME in NSCLC. Methods: Four publicly available datasets were used to evaluate the impact of key enzymes involved in collagen biosynthesis. To investigate the influence of RASi intake on the TME and prognosis we evaluated a cohort of metastatic NSCLC patients and performed histopathological characterization of the TME. A three-dimensional microtissue in vitro model was developed to define the impact of RASi on collagen synthesis. Results: Expression of three genes of the collagen synthesis pathway, ALDH18A1, PLOD2 and P4HA1, was upregulated in NSCLC compared to normal lung tissue and linked to shortened overall survival in all investigated cohorts. Together, these genes formed a 'Collagen Signature' which represents an independent unfavourable prognostic factor in two NSCLC cohorts and was linked to alterations of the extracellular matrix deposition and cell cycle pathways. In the cohort of metastatic NSCLC, RASi intake was linked to improved overall response rate and survival. Exploratory in vitro experiments revealed that RASi led to a dose dependent reduction of collagen deposition and degradation of three-dimensional lung cancer cell spheroids. Conclusion: We demonstrate that collagen synthesis is a key upregulated process in the NSCLC TME and its transcriptional readout, the three gene Collagen Signature is independently associated with poor outcome. Pharmacological targeting of this pathways e.g. by RASi bears potential of improving outcome in NSCLC.
Effect of Selol on Tumor Morphology and Biochemical Parameters Associated with Oxidative Stress in a Prostate Tumor-Bearing Mice Model

Małgorzata Sochacka,Grażyna Hoser,Małgorzata Remiszewska,Piotr Suchocki,Krzysztof Sikora,Joanna Giebułtowicz

DOI: https://doi.org/10.3390/nu16172860

IF: 5.9

2024-08-28

Nutrients

Abstract:Prostate cancer is the leading cause of cancer death in men. Some studies suggest that selenium Se (+4) may help prevent prostate cancer. Certain forms of Se (+4), such as Selol, have shown anticancer activity with demonstrated pro-oxidative effects, which can lead to cellular damage and cell death, making them potential candidates for cancer therapy. Our recent study in healthy mice found that Selol changes the oxidative–antioxidative status in blood and tissue. However, there are no data on the effect of Selol in mice with tumors, considering that the tumor itself influences this balance. This research investigated the impact of Selol on tumor morphology and oxidative–antioxidative status in blood and tumors, which may be crucial for the formulation's effectiveness. Our study was conducted on healthy and tumor-bearing animal models, which were either administered Selol or not. We determined antioxidant enzyme activities (Se-GPx, GPx, GST, and TrxR) spectrophotometrically in blood and the tumor. Furthermore, we measured plasma prostate-specific antigen (PSA) levels, plasma and tumor malondialdehyde (MDA) concentration as a biomarker of oxidative stress, selenium (Se) concentrations and the tumor ORAC value. Additionally, we assessed the impact of Selol on tumor morphology and the expression of p53, BCL2, and Ki-67. The results indicate that treatment with Selol influences the morphology of tumor cells, indicating a potential role in inducing cell death through necrosis. Long-term supplementation with Selol increased antioxidant enzyme activity in healthy animals and triggered oxidative stress in cancer cells, activating their antioxidant defense mechanisms. This research pathway shows promise in understanding the anticancer effects of Selol. Selol appears to increase the breakdown of cancer cells more effectively in small tumors than in larger ones. In advanced tumors, it may accelerate tumor growth if used as monotherapy. Therefore, further studies are necessary to evaluate its efficacy either in combination therapy or for the prevention of recurrence.

nutrition & dietetics
Effects of Selenium Yeast on Oxidative Stress, Growth Inhibition, and Apoptosis in Human Breast Cancer Cells

Chih-Hung Guo,Simon Hsia,Min-Yi Shih,Fang-Chin Hsieh,Pei-Chung Chen

DOI: https://doi.org/10.7150/ijms.12177

2015-01-01

International Journal of Medical Sciences

Abstract:Recent evidence suggests that selenium (Se) yeast may exhibit potential anti-cancer properties; whereas the precise mechanisms remain unknown. The present study was aimed at evaluating the effects of Se yeast on oxidative stress, growth inhibition, and apoptosis in human breast cancer cells. Treatments of ER-positive MCF-7 and triple-negative MDA-MB-231 cells with Se yeast (100, 750, and 1500 ng Se/mL), methylseleninic acid (MSA, 1500 ng Se/mL), or methylselenocysteine (MSC, 1500 ng Se/mL) at a time course experiment (at 24, 48, 72, and 96 h) were analyzed. Se yeast inhibited the growth of these cancer cells in a dose- and time-dependent manner. Compared with the same level of MSA, cancer cells exposure to Se yeast exhibited a lower growth-inhibitory response. The latter has also lower superoxide production and reduced antioxidant enzyme activities. Furthermore, MSA (1500 ng Se/mL)-exposed non-tumorigenic human mammary epithelial cells (HMEC) have a significant growth inhibitory effect, but not Se yeast and MSC. Compared with MSA, Se yeast resulted in a greater increase in the early apoptosis in MCF-7 cells as well as a lower proportion of early and late apoptosis in MDA-MB-231 cells. In addition, nuclear morphological changes and loss of mitochondrial membrane potential were observed. In conclusion, a dose of 100 to 1500 ng Se/mL of Se yeast can increase oxidative stress, and stimulate growth inhibitory effects and apoptosis induction in breast cancer cell lines, but does not affect non-tumorigenic cells.

medicine, general & internal
Selenium targets resistance biomarkers enhancing efficacy while reducing toxicity of anti-cancer drugs: preclinical and clinical development

Yousef Zakharia,Arup Bhattacharya,Youcef M. Rustum

DOI: https://doi.org/10.18632/oncotarget.24297

2018-01-23

Oncotarget

Abstract:Selenium (Se)-containing molecules exert antioxidant properties and modulate targets associated with tumor growth, metastasis, angiogenesis, and drug resistance. Prevention clinical trials with low-dose supplementation of different types of Se molecules have yielded conflicting results. Utilizing several xenograft models, we earlier reported that the enhanced antitumor activity of various chemotherapeutic agents by selenomethione and Se-methylselenocysteine in several human tumor xenografts is highly dose- and schedule-dependent. Further, Se pretreament offered selective protection of normal tissues from drug-induced toxicity, thereby allowing higher dosing than maximum tolerated doses. These enhanced therapeutic effects were associated with inhibition of hypoxia-inducible factor 1- and 2-alpha (HIF1α, HIF2α) protein, nuclear factor (erythyroid-derived 2)-like 2 (Nrf2) and pair-related homeobox-1 (Prx1) transcription factors, downregulation of oncogenic- and upregulation of tumor suppressor miRNAs. This review provides: 1) a brief update of clinical prevention trials with Se; 2) advances in the use of specific types, doses, and schedules of Se that selectively modulate antitumor activity and toxicity of anti-cancer drugs; 3) identification of targets selectively modulated by Se; 4) plasma and tumor tissue Se levels achieved after oral administration of Se in xenograft models and cancer patients; 5) development of a phase 1 clinical trial with escalating doses of orally administered selenomethionine in sequential combination with axitinib to patients with advanced clear cell renal cell carcinoma; and 6) clinical prospects for future therapeutic use of Se in combination with anticancer drugs.

Mass spectrometry based proteomic profiling for pancreatic cancer.

Essential role of a kinesin-like protein in Arabidopsis trichome morphogenesis.

Predicting rib fracture risk with whole-body finite element models: development and preliminary evaluation of a probabilistic analytical framework.

Effect of Selenium on the Expression of Fas/FasL in T Lymphocyte Anti Colonic Cancer Cells

Response Surface Methodology Optimizes Selenium Inhibition of Prostate Cancer PC-3 Cell Viability

Effect of selenium-containing compounds on hepatic chemoprotective enzymes in mice

Preliminary Study of Selenium (Se) Toxicity in Human Prostate Carcinoma (PC3) Cells with the Overexpression of Selenocysteine Synthase ( SecS ) Gene

Hyaluronan participates in the epidermal response to disruption of the permeability barrier in vivo.

Selenomethionine Stimulates MAPK (ERK) Phosphorylation, Protein Oxidation, and DNA Synthesis in Gastric Cancer Cells

Selenium and the 15kDa Selenoprotein Impact Colorectal Tumorigenesis by Modulating Intestinal Barrier Integrity

Survivin gene silencing sensitizes prostate cancer cells to selenium growth inhibition

Differential epigenetic profiles induced by sodium selenite in breast cancer cells

Studying the impact of selenium complex chemical structure on collagen-starch hydrogels for enhanced tissue growth

Mitochondria-Mediated Protein Regulation Mechanism of Polymorphs-Dependent Inhibition of Nanoselenium on Cancer Cells

Selenium speciation studies in cancer patients to evaluate the responses of biomarkers of selenium status to different selenium compounds

The Nutritional Prevention of Cancer: 400 Mcg Per Day Selenium Treatment

Antitumor Effects of Selenium

Deregulated glutamate to pro-collagen conversion is associated with adverse outcome in lung cancer and may be targeted by renin-angiotensin-aldosterone system (RAS) inhibition

Effect of Selol on Tumor Morphology and Biochemical Parameters Associated with Oxidative Stress in a Prostate Tumor-Bearing Mice Model

Effects of Selenium Yeast on Oxidative Stress, Growth Inhibition, and Apoptosis in Human Breast Cancer Cells

Selenium targets resistance biomarkers enhancing efficacy while reducing toxicity of anti-cancer drugs: preclinical and clinical development